Diagnostic test kit, 'FLU OIA', optical immunoassay for the detection of influenza A and B, paper / plastic / cardboard / liquid reagents / monoclonal antibodies / calf serum, developed and made by Biota, Melbourne, Victoria, Australia / Thermo Electron Corporation, Louisville, Colorado, United States of America, 2004
FLU OIA is the first clinical test capable of scientifically confirming in 15 minutes that a person is infected with an influenza virus. It allows doctors to identify patients likely to benefit from neuraminidase inhibitor drugs, which are effective against all strains of flu if taken within 48 hours of the first symptoms. Used together with neuraminidase inhibitor drugs, FLU OIA will form the first line of defence against the next influenza pandemic when it strikes. Appropriate vaccine will not be available for about six months after the pandemic strain emerges, so FLU OIA will be of enormous significance to humanity in the battle against influenza. It will play a key role in disease management in that accurate diagnosis allows appropriate treatment and limitation of spread of the disease throughout the community.
FLU OIA was co-developed by Biota, the same Australian company that developed Relenza, the first neuraminidase inhibitor drug. The company is a world leader in anti-viral research. Both FLU OIA and neuraminidase drugs like Relenza have enormous scientific and social significance. Used together, they can identify, treat and help contain the spread of influenza, a disease capable of killing millions of people in a matter of months.
The FLU OIA - Influenza diagnostic test kit was developed jointly by Biota Holdings and the US company, Thermo Electron. It was launched in the USA in December 1998.
This kit was produced in the USA by Thermo Electron Corporation. In the USA it is manufactured and marketed by Thermo Electron. Biota holds the marketing and distribution rights outside the USA and its major distributors are Daiichi Pure Chemical Co., Ltd in Japan and Dade Behring in Australia.